Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS
4 března, 2021 6:43 pmAuthor(s): Jakob Werner Hansen, Maj Westman, Andreas Due Orskov, et al. Abstract: S 486 Session topic: 10. Myelodysplastic...
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
4 března, 2021 6:40 pmAuthor(s): Aaron T. Gerds, Bart L. Scott, Peter Greenberg, et al. Abstract: P 662 Session topic: 10. Myelodysplastic...
DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE
4 března, 2021 6:38 pmAuthor(s): M Teresa Cedena, Fátima Mirás, Rosa M Ayala, et al. Abstract: P 661 Session topic: 9. Myelodysplastic...
UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
4 března, 2021 6:36 pmAuthor(s): Guillermo Montalban-Bravo, Prithviraj Bose, Yesid Alvarado, et al. Abstract: P 315 Session topic: 10. Myelodysplastic syndromes –...
Kongres Evropské hematologické společnosti
4 března, 2021 6:34 pmV rámci každoročního kongresu Evropské hematologické společnosti, jež se konal ve dnech 22. až 25. června 2017 v Madridu (Španělsko), bylo prezentováno několik...
SATELLITE SYMPOSIUM REPORT
4 března, 2021 6:26 pmOn 22 June 2017, a satellite symposium on „What is relevant for chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia“...
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
4 března, 2021 6:21 pmAuthor(s): David Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia Gutierrez, Norbert Gattermann,...
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
4 března, 2021 6:18 pmAuthor(s): Timothy Hughes, Carla Boquimpani, Naoto Takahashi, Noam Benyamini, Nelma Cristina Clementino, Vasily Shuvaev, Sikander Ailawadhi, Jeffrey Lipton, Anna Turkina,...
5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
4 března, 2021 6:16 pmAuthor(s): Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et al. Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et...
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
4 března, 2021 6:13 pmAuthor(s): Ruediger Hehlmann, Michael Lauseker, Susanne Saussele, et al. Abstract: S424 Session topic: 8. Chronic myeloid leukemia –...